Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. (Q55067415)
Jump to navigation
Jump to search
scientific article published in November 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. |
scientific article published in November 2014 |
Statements
1 reference
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. (English)
1 reference
1 reference
Laura Concas
1 reference
Cristina Bregant
1 reference
Livia Leuzzi
1 reference
Barbara Formisano
1 reference
Roberto Buzzoni
1 reference
1 November 2014
1 reference
1 reference
100
1 reference
6
1 reference
e286-9
1 reference
Identifiers
1 reference